Trials / Completed
CompletedNCT00910741
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
Phase I/II Study of the Combination Therapy With NC-6004 and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer in Asian Countries
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- NanoCarrier Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nanoplatin (NC-6004) and Gemcitabine |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2009-06-01
- Last updated
- 2014-01-09
Locations
5 sites across 2 countries: Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00910741. Inclusion in this directory is not an endorsement.